| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7 (1), 57, 2019 | 430 | 2019 |
| Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors M Bersanelli Immunotherapy 12 (5), 269-273, 2020 | 253 | 2020 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 194 | 2019 |
| L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC M Bersanelli, R Minari, P Bordi, L Gnetti, C Bozzetti, A Squadrilli, ... Journal of thoracic oncology 11 (10), e121-e123, 2016 | 193 | 2016 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 192 | 2019 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 160 | 2021 |
| Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 … T van der Hulle, PL Den Exter, B Planquette, G Meyer, S Soler, M Monreal, ... Journal of Thrombosis and Haemostasis 14 (1), 105-113, 2016 | 151 | 2016 |
| Chemotherapy in metastatic renal cell carcinoma today? A systematic review S Buti, M Bersanelli, A Sikokis, F Maines, F Facchinetti, E Bria, A Ardizzoni, ... Anti-cancer drugs 24 (6), 535-554, 2013 | 129 | 2013 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 128 | 2020 |
| Soluble PD-L1 and circulating CD8+ PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients G Mazzaschi, R Minari, A Zecca, A Cavazzoni, V Ferri, C Mori, A Squadrilli, ... Lung Cancer 148, 1-11, 2020 | 112 | 2020 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 111 | 2021 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 91 | 2020 |
| Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) SE Rebuzzi, A Signori, GL Banna, M Maruzzo, U De Giorgi, P Pedrazzoli, ... Therapeutic advances in medical oncology 13, 17588359211019642, 2021 | 89 | 2021 |
| Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population S Buti, M Puligandla, M Bersanelli, RS DiPaola, J Manola, S Taguchi, ... Annals of Oncology 28 (11), 2747-2753, 2017 | 86 | 2017 |
| Sex hormones and hormone therapy during COVID-19 pandemic: implications for patients with cancer C Cattrini, M Bersanelli, MM Latocca, B Conte, G Vallome, F Boccardo Cancers 12 (8), 2325, 2020 | 81 | 2020 |
| From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis M Bersanelli, S Buti World journal of clinical oncology 8 (1), 37, 2017 | 81 | 2017 |
| Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy S Buti, A Leonetti, A Dallatomasina, M Bersanelli Core evidence, 23-36, 2016 | 79 | 2016 |
| The gut microbiome and efficacy of cancer immunotherapy G Roviello, LF Iannone, M Bersanelli, E Mini, M Catalano Pharmacology & Therapeutics 231, 107973, 2022 | 75 | 2022 |
| The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors F Perrone, R Minari, M Bersanelli, P Bordi, M Tiseo, E Favari, R Sabato, ... Journal of Immunotherapy 43 (6), 196-203, 2020 | 70 | 2020 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 67 | 2020 |
